Mesothelioma Clinical Trials

A mesothelioma diagnosis is a serious one, but it is not one without hope. There are a variety of treatments available, and a number of ongoing clinical trails.

Trial Status

We do our best to keep the current status (closed, currently recruiting, upcoming) of each clinical trial up-to-date. Several clinical trials are listed at ClinicalTrials.gov as "currently recruiting" despite the estimated completion date having been long past. The contact for a particular clinical trial is your best bet to discover if a particular clinical trial is still open and recruiting.

Glossary

To help you as you read through these clinical trials, we have glossary of terms and their definitions. Words underlined with a dashed line are part of the glossary; to see their definition, simply click on the word.

Clinical Trials

Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies

Primary Outcome Measures Initial efficacy of LUM015 in labeling peritoneal surface malignancies by molecular imaging by comparing imaging results with pathology [ Time Frame: 1 Day ] Correlate the fluorescence levels in tumor tissue imaging to the dose of LUM015 injected. Secondary Outcome Measures Number of patients with reported adverse events [ Time Frame: ... [More >>]

Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes

Primary Outcome Measures Incidence and frequencies of Cancers [ Time Frame: ongoing ] Standard exploratory and descriptive measures will be used. Counts, incidence, and frequencies of cancers identified via screening procedures on this trial will be reported, all in the context of an exploratory study with appropriate caveats. Inclusion Criteria for Genetic Testing Cohort ... [More >>]

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

Primary Outcome Measures Major Pathological Response (mPR) [ Time Frame: From screening pathology to an average of 15 weeks after first dose. ] Secondary Outcome Measures Pathological complete response (pCR) [ Time Frame: From screening pathology to an average of 15 weeks after first dose. ] Overall Survival (OS) [ Time Frame: From date ... [More >>]

A Study of Atezolizumab in Unresectable or Advanced Malignant Pleural Mesothelioma

Primary Outcome Measures Objective Response Rate [ Time Frame: From the time of initial response until documented tumor progression or death, whichever occurs first (up to approximately 4 years) ] The number of subjects whose best confirmed objective response is a CR or PR, divided by the number of treated subjects Secondary Outcome ... [More >>]

BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma (BEAT-meso)

Primary Outcome Measures Progression-free Survival (PFS) according to the mRECIST v1.1 [ Time Frame: From date of randomisation until documented progression or death, if progression is not documented, assessed up to 67 months ] A co-primary endpoint, defined as the time from the date of randomisation until documented progression (according to the ... [More >>]

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Primary Outcome Measures Study related adverse events (AEs) [ Time Frame: Each subjects will be assessed for AEs from the time of their first study treatment until 30 days after the end of their treatment for AEs and until 90 days after their last treatment for serious AEs (study treatment may ... [More >>]

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Primary Outcome Measures Adverse Events (Part 1 and Part 2) [Time Frame: Approximately 24 months] Objective response rate (ORR) (Part 2) [Time Frame: Approximately 24 months] Secondary Outcome Measures Maximum observed concentration (Cmax) of rebastinib [ Time Frame: Cycle 1 Day 1, Cycle 2 Day 1 (each cycle is 21 days) ] Measure the Cmax Area ... [More >>]

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Primary Outcome Measures Frequency and severity of adverse events of INBRX-109 [ Time Frame: Up to 2 years ] Adverse events will be assessed and severity assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) ... [More >>]

Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma (INFINITE)

Primary Outcome Measures Overall Survival [ Time Frame: 60 months ] Time to death (from any cause) from randomization Secondary Outcome Measures Survival rate [ Time Frame: 60 months ] Number of deaths (from any ... [More >>]

Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers

Primary Outcome Measures Pre-treatment Prognostic Algorithm Validation [ Time Frame: 4 years ] The primary outcome will be to prospectively validate a pre-treatment prognostic algorithm to predict survival for MPM patients. Secondary Outcome Measures Evaluation of Molecular Tests Base on RNA Expression [ Time Frame: 4 years ] A secondary outcome will be to evaluate molecular tests that are based ... [More >>]

Last update: January 19, 2018. 04:57:31 pm.